Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
First received: October 9, 2005
Last updated: February 11, 2013
Last verified: February 2013
An open, multicenter and prospective study to evaluate the impact of the treatment with zoledronic acid 4 mg, on the quality of life and the skeletal-related events in patients with prostate cancer and bone metastasis that responds to hormonal therapy. Zoledronic acid is given to patients in a 15 minute-infusion every 4 weeks until a skeletal-related event occurs.
Drug: Zoledronic acid
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy.
Primary Outcome Measures:
- Evaluate the effects of Zometa® (Zoledronic Acid) i.v in doses of 4mg for measure the following parameters of efficacy: Quality of Life, Incidence of Events related to the skeleton
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||March 2008 (Final data collection date for primary outcome measure)
Experimental: Zoledronic Acid
Drug: Zoledronic acid
Other Name: ZOL446
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Age ≥18
- histologically confirmed adenocarcinoma of the prostate.
- Orchidectomy within the four previous weeks to enter the study.
- bone metastasis evidenced by bone scan.
- A hip DEXA study with a DS < 3.
- No hormonal therapy previous to enter the study.
- ECOG performance score of 0-2.
- Signed written informed consent.
- Abnormal renal function evidenced by a creatinine clearance ≤60 ml/min.
- Any kind of hormonal therapy for prostate cancer previous to enter the study.
- Serum calcium corrected for albumin level < 8.0 mg/dl.
- WBC < 3.0x10^3, ANC < 1500/mm3, Hemoglobin < 8.0 g/dl, platelets < 75 x 10^3/l.
- Abnormal hepatic function evidenced by ALT and AST value >2.5 UNL
- Subjects with any other malignant disease that can affect the bone.
- Subjects with any other non malignant disease that can jeopardize the evaluation of the primary objectives of this trial (severe osteoporosis) or that do not aloud perform the trial evaluations.
- Known hypersensibility to zoledronic acid or other bisphosphonates.
- Subjects that in the investigator's opinion can not cooperate with the protocol.
Other protocol inclusion/exclusion criteria may apply.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00237146
|Novartis Investigative Site
|Caracas, Venezuela |
No publications provided
||Novartis ( Novartis Pharmaceuticals )
History of Changes
|Other Study ID Numbers:
|Study First Received:
||October 9, 2005
||February 11, 2013
||Venezuela: Ministry of Health and Social Development
Keywords provided by Novartis:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on November 23, 2014
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Site
Bone Density Conservation Agents
Physiological Effects of Drugs